Lyra Therapeutics Future Growth
Future criteria checks 2/6
Lyra Therapeutics is forecast to grow earnings and revenue by 12.6% and 56.6% per annum respectively while EPS is expected to grow by 19.5% per annum.
Key information
12.6%
Earnings growth rate
19.5%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | 56.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 26 | -98 | -87 | -80 | 3 |
| 12/31/2025 | 1 | -82 | -77 | -71 | 6 |
| 12/31/2024 | 1 | -69 | -66 | -67 | 6 |
| 12/31/2023 | 2 | -63 | -64 | -63 | N/A |
| 9/30/2023 | 1 | -62 | -57 | -56 | N/A |
| 6/30/2023 | 1 | -61 | -53 | -53 | N/A |
| 3/31/2023 | 1 | -60 | -47 | -47 | N/A |
| 12/31/2022 | 1 | -55 | -44 | -43 | N/A |
| 9/30/2022 | 2 | -55 | -44 | -43 | N/A |
| 6/30/2022 | 1 | -51 | -44 | -42 | N/A |
| 3/31/2022 | 1 | -48 | -32 | -30 | N/A |
| 12/31/2021 | 0 | -44 | -29 | -26 | N/A |
| 9/30/2021 | 0 | -37 | -24 | -20 | N/A |
| 6/30/2021 | N/A | -32 | -17 | -14 | N/A |
| 3/31/2021 | N/A | -26 | -28 | -25 | N/A |
| 12/31/2020 | N/A | -22 | -23 | -21 | N/A |
| 9/30/2020 | N/A | -20 | -20 | -19 | N/A |
| 6/30/2020 | N/A | -18 | -19 | -19 | N/A |
| 3/31/2020 | N/A | -17 | -15 | -15 | N/A |
| 12/31/2019 | N/A | -17 | -14 | -14 | N/A |
| 12/31/2018 | 1 | -6 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LYRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LYRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LYRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LYRA's revenue (56.6% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: LYRA's revenue (56.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LYRA's Return on Equity is forecast to be high in 3 years time